Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity
Fuse a cancer cell to an immune cell, and you can brew one pure antibody, forever.
What if you could take one immune cell that makes the exact antibody you want — and make it live and copy itself forever?
The big idea
Your immune system makes antibodies: Y-shaped proteins that grip one specific target, like a molecular lock-and-key. The trouble is that the cells which make a single, pure antibody die quickly in a dish, so for a century the only way to get antibodies was to bleed an animal and collect a messy mixture — different every time.
Köhler and Milstein solved it with a trick of fusion. They glued an antibody-making immune cell to a cancer cell, which is immortal, making a single hybrid that inherited both gifts: it lives forever and it keeps pouring out that one pure antibody. They called it a hybridoma, and its product a monoclonal antibody.
How it came about
In 1975, at the Laboratory of Molecular Biology in Cambridge, César Milstein — a quiet, generous Argentine biochemist — was studying how antibody-making tumour cells work. His German postdoc, Georges Köhler, had the idea of fusing such a tumour cell to a normal immune cell from a mouse immunised against sheep blood cells.
The masterstroke was how to keep only the fusions. They grew the dish in a poison (called HAT) that the cancer cells couldn't survive on their own and the normal cells couldn't grow in — but the hybrids could do both, so only they lived. The pair reported it in a two-page note in Nature, and ended with quiet understatement: such cultures could be valuable for medical and industrial use. They were not exaggerating. Famously, no one patented it.
Why it mattered
A monoclonal antibody is a reagent of perfect, repeatable aim — it sticks to one chosen thing and nothing else, batch after batch, forever. That turned antibodies from a natural product you harvested into a tool you could design and manufacture. It is why a home pregnancy test works, why many cancers and autoimmune diseases now have targeted drugs, and why a rapid COVID test can light up in fifteen minutes.
A way to picture it
Think of an immune cell as a brilliant artisan who can carve exactly one perfect key — but who is mortal and works alone. The cancer cell is a tireless copy-machine with nothing worth copying. Fuse them, and you get an immortal workshop that stamps out that one perfect key, identical, by the million, for as long as you keep the lights on.
Where it sits
This is the moment antibodies entered the engineering age. It builds on a century that began with vaccines (Jenner, 1798) and the discovery that serum carries protective antibodies, and it dovetails with the new molecular biology of DNA (Watson & Crick, 1953) and recombinant techniques. From here the thread runs straight to humanised antibodies, antibody-drug conjugates, and the targeted biologics that dominate today's pharmacy shelves.
The manufacture of predefined specific antibodies by means of permanent tissue culture cell lines is of general interest.
Such cultures could be valuable for medical and industrial use.